Board of Directors
Peter K. Miller
Peter Miller joined the Board of Directors of OptiNose AS in 2008 when he first became familiar with the Company’s unique approach to nasal drug delivery and convinced of the potential for using it to create clinically important new products. In 2010, in partnership with Ramy Mahmoud, Mr. Miller led the start-up of Optinose in collaboration with Avista Capital Partners, acquiring OptiNose AS and accepting the role of CEO.
Mr. Miller was previously the Co-Founder, CEO and President of Take Care Health Systems, a company that disrupted the US healthcare system through a revolutionary idea to operate medical clinics inside Walgreens retail pharmacies. Mr. Miller served as a Vice President in the Walgreens Health and Wellness Division and remained CEO for Take Care Health Systems for three years after its sale to Walgreens, growing the clinical operation to more than 400 clinics nationwide.
Earlier, Mr. Miller spent more than 15 years at Johnson & Johnson, serving in a variety of marketing and general management roles that included Worldwide President of Johnson & Johnson – Merck Consumer Pharmaceuticals and President of Janssen Pharmaceuticals, a $4 billion pharmaceutical company. While at Johnson & Johnson, he played an integral role in building brands such as Tylenol, Motrin, Imodium, Pepcid, Duragesic, Risperdal and Aciphex. Mr. Miller also serves as a member of the Board of Directors of Actua Corporation, a publicly held SaaS technology company.
Mr. Miller earned an economics degree from Trinity College and an MBA from the Kellogg School of Management at Northwestern University.
Larry G. Pickering
Larry G. Pickering joined the Optinose Board of Directors in 2010, first serving as Chairman and now as Vice Chairman of the Board. Most recently, Mr. Pickering served as World Wide Healthcare Partner for Avista Capital, a private equity firm from its founding until 2014.
Previously, he had a 32-year career in healthcare with Johnson & Johnson, where he served as President of Ortho Dermatology; President of Janssen Pharmaceuticals and Chairman of Janssen North America; Company Group Chairman of Worldwide OTC; Chairman of Johnson & Johnson Development Corporation; and a Corporate Officer. Mr. Pickering retired from Johnson & Johnson in 2005. Mr. Pickering previously served as Chairman of the Board of Directors of Lantheus Medical Imaging, a medical imaging company with public securities, and as Chairman of DLJMB Global Healthcare Partners, an investment firm.
Mr. Pickering holds a BBA from the University of Missouri.
William F. Doyle
William F. Doyle has served on the Optinose Board of Directors since 2010. Mr. Doyle is the managing partner of WFD Ventures LLC, a private venture capital firm he co-founded, and was a member of the investment team of Pershing Square Capital Management, a private investment firm.
Previously, Mr. Doyle served as a member of Johnson & Johnson’s Medical Devices and Diagnostics Group Operating Committee and was Vice President, Licensing and Acquisitions. While at Johnson & Johnson, Mr. Doyle was also Chairman of the Medical Devices Research and Development Council and worldwide President of Biosense-Webster. Earlier in his career, Mr. Doyle was a management consultant in the healthcare group of McKinsey & Company. Mr. Doyle is the Executive Chairman of Novocure, a commercial-stage oncology company, and the Executive Chairman of Blink Health, a private technology company providing Americans with affordable access to prescription medications. He previously served as director of Zoetis, an animal medicine and vaccine company.
Mr. Doyle earned an SB in materials science and engineering from the Massachusetts Institute of Technology and an MBA from Harvard Business School.
Sriram Venkataraman has served as a Director of Optinose since 2010. He is also a Partner of Avista, having joined in 2007. Prior to Avista, Mr. Venkataraman was a Vice President in the Healthcare Investment Banking group at Credit Suisse Group AG. Previously, he worked at GE Healthcare (formerly known as GE Medical Systems) from 1996 to 1999. He currently serves as a director of Osmotica Holdings; National Spine & Pain Centers Holdings; Zest Anchors; and Miraca Life Sciences, Inc, and its direct and indirect parent companies. Mr. Venkataraman previously served as a director of AngioDynamics and Lantheus Holdings.
Mr. Venkataraman holds an MS in electrical engineering from the University of Illinois, Urbana-Champaign, and an MBA from the Wharton School at the University of Pennsylvania.
Joshua A. Tamaroff
Joshua A. Tamaroff joined the Optinose Board of Directors in March 2017. He joined Avista in 2009 and currently serves as a Vice President. Prior to Avista, Mr. Tamaroff worked as an analyst in the leveraged finance group at Lehman Brothers and Barclays Capital. Mr. Tamaroff currently serves as a director of IWCO Direct and WideOpenWest. He previously served as a director of InvestorPlace Media.
Mr. Tamaroff earned a BS from Cornell University and a MBA from the Wharton School at the University of Pennsylvania, where he was a Palmer Scholar.
Joseph C. Scodari
Joseph C. Scodari has served as Chairman of the Optinose Board of Directors since October 2017. Mr. Scodari was Worldwide Chairman, Pharmaceuticals Group, of Johnson & Johnson, and a member of Johnson & Johnson’s Executive Committee. He also served as Company Group Chairman of Johnson & Johnson’s Biopharmaceutical Business. Mr. Scodari joined Johnson & Johnson in 1999 as President of Centocor, when Johnson & Johnson acquired that company.
Prior to Johnson & Johnson, he served as Centocor’s President, Pharmaceutical Division, and was later named President and Chief Operating Officer. Mr. Scodari began his career in 1974 in sales for Winthrop Laboratories, a division of Sterling Drug. He progressed through various management positions, eventually leading the Diagnostic Imaging Division for Winthrop and later Strategic Marketing at the Corporate level for the imaging business. Mr. Scodari joined Rorer Pharmaceuticals (shortly thereafter, Rhône-Poulenc Rorer) in 1989 as Vice President of Marketing and Business Development. He later served as Vice President and General Manager for the United States and subsequently North America, and finally as Senior Vice President and General Manager for the Americas.
Mr. Scodari previously served as a director of Actelion Pharmaceuticals, Endo Health Solutions and Covance. Mr. Scodari served on various nonprofit boards, including the University of the Health Sciences in Philadelphia, the Board of Overseers for the Robert Wood Johnson School of Medicine and the Board of Trustees for Gwynedd Mercy College. He also served on various industry association boards including the NWDA Associate Member Board, the National Pharmaceutical Council, as Vice Chairman of the Biotechnology Industry Organization (BIO), and as Chairman of PA BIO.
Mr. Scodari received a BA from Youngstown State University.
Wilhelmus Groenhuysen joined the Optinose Board of Directors in October 2017. He is currently Chief Financial Officer of NovoCure Limited. Previously, he was Executive Vice President and Chief Financial Officer at Cephalon. Prior to joining Cephalon, Mr. Groenhuysen spent 20 years with Philips Electronics serving various assignments in Europe, Asia and the United States, most recently as Chief Financial Officer and Senior Vice President of Philips Electronics North America Corporation.
Mr. Groenhuysen holds a Master’s Degree in business economics from VU University Amsterdam and graduated as a Registered Public Controller at VU University Amsterdam.
Sandra L. Helton
Sandra L. Helton joined the Optinose Board of Directors in February 2018. Ms. Helton serves on the Board of Directors of Principal Financial Group, a global diversified financial institution, where she chairs the Audit Committee and serves on Principal’s Executive Committee and Finance Committee, which she previously chaired.
Ms. Helton was Executive Vice President, Chief Financial Officer and member of the Board of Directors of Telephone and Data Systems, Inc. from 1998 through 2006. Her responsibilities included strategic planning, finance and information systems, among other functions. Ms. Helton also served on the Boards of United States Cellular Corporation and Aerial Corporation, TDS’s publicly traded subsidiaries. Before TDS, Ms. Helton was Vice President, Corporate Controller of Compaq Computer Corporation. Prior to Compaq, Ms. Helton held over a dozen positions of increasing responsibility during her 26-year tenure with Corning Incorporated.
Prior to the acquisition of Lexmark International Inc. in November 2016, Ms. Helton served on their Board of Directors and Finance and Audit Committee. She also served on the board of Covance Inc., a leading global drug development services company, prior to the company’s acquisition by LabCorp in 2015. She chaired the Finance and Audit Committee and served on the Nominating and Governance Committee of Covance.
Ms. Helton serves on the Board and Executive Committee of Northwestern Memorial Foundation. She previously served on the Board of Northwestern Memorial Health Care, a nationally recognized academic medical center, where she chaired the Audit Committee and was a member of the Executive, Finance and Investment Committees.
Ms. Helton earned an SM in finance from Massachusetts Institute of Technology’s Sloan School of Management and graduated summa cum laude with a BS in mathematics from the University of Kentucky.